Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks
Home
Publications
Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks
Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks
Authors:
FB
F. Berenbaum
F. Berenbaum
RL
R. Langford
R. Langford
SP
S. Perrot
S. Perrot
KM
K. Miki
K. Miki
FB
F.J. Blanco
F.J. Blanco
TY
T. Yamabe
T. Yamabe
NI
N. Isogawa
N. Isogawa
SA
S. Araki
S. Araki
RJ
R. Junor
R. Junor
WC
W. Carey
W. Carey
LV
L. Viktrup
L. Viktrup
CW
C.R. West
C.R. West
See more
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
1 April 2020
journal article
Published by
Elsevier
in
Osteoarthritis and Cartilage
Vol. 28
,
S144-S145
DOI:
10.1016/j.joca.2020.02.239
Abstract
No abstract available
Keywords
WOMAC
CLINICAL ENDPOINT
DISCONTINUATION
KNEE PAIN
Cited
Cited by 2 articles
Scroll to top